The University of Kansas Cancer Center (KUCC)
Welcome,         Profile    Billing    Logout  
 12 Trials 
3 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Shen, Xinglei
STEEL, NCT03809000: A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

Active, not recruiting
2
188
Canada, US
Radiation Therapy, RT, Image-Guided Radiation Therapy (IGRT), Radiotherapy, Enzalutamide, Xtandi®, Bicalutamide, Casodex®, GnRH analog, Gonadotropin-releasing hormone analog, Lupron®, leuprolide acetate, goserelin acetate, Eligard™, Viadur™, Zoladex®, Trelstar®
RTOG Foundation, Inc., Pfizer, Astellas Pharma Inc
Prostate Cancer
04/23
09/29
Navigator, KUCC
H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Active, not recruiting
1/2
200
Europe, US
HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)
Hookipa Biotech GmbH, Hookipa Biotech
HPV-Related Squamous Cell Carcinoma
06/25
06/26
CAMILLA, NCT03539822: Cabozantinib Plus Durvalumab with or Without Tremelimumab in Patients with Gastroesophageal Cancer and Other Gastrointestinal Malignancies

Checkmark Data from CAMILLA trial in combination with durvalumab in advanced CRC at ASCO GI 2022
Jan 2022 - Jan 2022: Data from CAMILLA trial in combination with durvalumab in advanced CRC at ASCO GI 2022
Recruiting
1/2
117
US
Cabozantinib, multi-tyrosine kinase Inhibitor, Durvalumab, anti-Programmed cell death protein 1 (PD-L1) inhibitor, Tremelimumab, Anti-CTLA4 inhibitor
Anwaar Saeed, AstraZeneca, Exelixis
Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Cancer
01/27
01/28

Download Options